BD drug-coated balloon falls short at FDA panel, signaling likely rejection

An FDA advisory panel voted against BD's Lutonix drug-coated balloon for treating peripheral artery disease below the knee, a second setback for the device in roughly 18 months and signaling a likely rejection for a premarket approval.